Jim Cramer Stock Picks: Summit Therapeutics Is A 'Great Spec' - Carvana (NYSE:CVNA)
Carvana reported Q2 revenue of $7.38B, above $6.91B estimates, and EPS of 42 cents vs 36 cents, according to Benzinga Pro. Jim Cramer highlighted Summit Therapeutics as a “great spec” after it reported a smaller-than-expected Q2 loss but said it lacks working capital for 12 months. He also discussed Forgent Power, NVE, and Reddit.
How this was made
The 30-second read
Why it matters
Traders can use the concrete datapoints (earnings beats, analyst initiation target, and SMMT’s working-capital insufficiency) to frame near-term positioning, but the article lacks forward guidance or detailed catalysts for some names.
Market read
Single-name catalysts are mixed: earnings beats support CVNA and RDDT, analyst initiation supports FPS, while SMMT’s working-capital warning raises financing/dilution risk.
What to watch
The article does not provide guidance, cash burn, or financing plans for SMMT, nor does it specify what drove NVEC’s surge beyond the prior Q1 improvement.
Background
The piece is a Jim Cramer stock-picks segment that references multiple companies’ recent earnings/coverage and reports same-day price moves.
Ticker impact
Cramer calls Summit Therapeutics a “great spec” after it reported a narrower-than-expected Q2 loss but disclosed insufficient working capital for 12 months.
Near-term volatility likely, with downside skew if funding needs rise or capital-raise timing becomes clearer.
The article’s actionable new element is the working-capital insufficiency disclosure tied to the Q2 results, which directly affects financing risk.
Carvana reported Q2 revenue of $7.38B and EPS of 42 cents, beating estimates, and the stock rose 6.1% on the day.
Supportive bias for the stock versus immediate expectations, but follow-through depends on any subsequent guidance not included here.
The article includes the earnings datapoints and same-day price action, but it is framed as part of a Cramer stock-picks segment with limited incremental detail.
Cramer said he needs to know more after NVE shares surged 5.7%, and the company reported a year-over-year increase in Q1 results on July 22.
Momentum could persist short term, but conviction is limited without the specific driver behind the surge.
The article attributes the move to “just moved up so much” without stating a new fundamental trigger in the text.
Reddit reported Q2 earnings of $1.25 per share, beating consensus, and shares jumped 10% to $154.71.
Likely continued bid if traders view the beat as durable, though the article lacks forward guidance details.
The earnings beat and same-day jump are concrete, but the piece does not add new forward-looking information.
Forgent Power shares jumped 9.1% to $36.29 after Cramer referenced it as “right versus the others,” and Baird initiated coverage with a $55 target.
Short-term upside bias while the market digests the initiation and target, with risk of mean reversion if no further catalysts emerge.
The article provides a concrete catalyst (coverage initiation and $55 target) alongside the reported jump.
Market effects
Highlights financing-risk sensitivity in small-cap biotech (SMMT) versus earnings-momentum sensitivity in consumer/tech-adjacent names (CVNA, RDDT).
No clear regional macro linkage beyond US-listed single-name moves.
Limited; primarily US single-stock catalysts.
Counterpoint
For SMMT, the “narrower-than-expected loss” may be less important than the working-capital shortfall, which can dominate valuation via dilution risk.
Key entities
- companySummit Therapeutics Inc.
Reported a narrower-than-expected Q2 loss but disclosed insufficient working capital to fund planned operations for the next 12 months.
- companyCarvana
Reported Q2 revenue of $7.38B and EPS of 42 cents, both beating estimates.
- companyNVE Corporation
Shares surged 5.7% after Cramer noted the move; company had reported a year-over-year increase in Q1 results on July 22.
- companyReddit, Inc.
Reported Q2 EPS of $1.25, beating consensus, and shares jumped 10%.
- companyForgent Power Solutions, Inc.
Shares jumped 9.1% after Baird initiated coverage with an Outperform rating and a $55 price target.
